Effect of Diabetes Mellitus on Hypogonadism in Chronic Renal Failure
DOI:
https://doi.org/10.31964/mltj.v8i1.467Abstract
Hypogonadism in male patients with chronic renal failure and diabetes mellitus has been known separately; up to now, the effect of these two diseases together on testosterone deficiency and the impact of testosterone deficiency on metabolic values have not been known precisely, therefore in this study we aimed to investigate testosterone deficiency in patients with diabetes mellitus and chronic renal failure. Eighty-seven chronic renal failure patients and 45 control patients who were followed at endocrinology and nephrology clinics were included in the study. After exclusion criteria, the patients were divided into two groups according to diabetes mellitus status. Groups were compared according to testosterone levels. Testosterone deficiency and good groups were compared to blood glucose, Hba1c, and lipid profile levels. The mean age of 87 CRF patients and 45 people in the control group were similar (59.85 ± 9.99 and 56.67 ± 8.56, respectively, p= 0.16). Testosterone deficiency was 24.1% (21/87) in CRF group and 8.8% (4/45) in control group (p= 0.04). The total testosterone levels were notably lower in the diabetic-CRF patients, 3.44 ± 1.3 vs. 4.26 ± 1.46 mg/dl (p= 0.02). The testosterone deficient CRF group had higher blood glucose and HbA1c according to the testosterone sufficient group. (161.20 ± 61.24 mg/dl vs 133.25 ± 59.87 mg/dl blood glucose, p= 0.04 and 7.54 ± 1.46 vs 6.79 ± 1.14 % HbA1c, p= 0.04). Serum triglyceride and LDL levels did not significantly change between groups (p= 0.20 and 0.76, respectively). Testosterone deficiency in male CRF patients is not uncommon. Male patients with both T2DM and CRF have more common testosterone deficiency. In testosterone-sufficient patients, blood glucose regulation was better. Therefore, in these patients, it may be helpful not to neglect testosterone deficiency, which affects gonadal function, body metabolism, and cardiac and skeletal health.References
Ballal, S. H., Domoto, D. T., Polack, D. C., Marciulonis, P., & Martin, K. J. (1991). Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 17(1), 29–33. https://doi.org/10.1016/s0272-6386(12)80246-0
Barrett-Connor, E., Khaw, K. T., & Yen, S. S. (1990). Endogenous sex hormone levels in older adult men with diabetes mellitus. American Journal of Epidemiology, 132(5), 895–901. https://doi.org/10.1093/oxfordjournals.aje.a115732
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Montori, V. M., & Task Force, Endocrine Society. (2010). Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 95(6), 2536–2559. https://doi.org/10.1210/jc.2009-2354
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000). Role of the brain insulin receptor in control of body weight and reproduction. Science (New York, N.Y.), 289(5487), 2122–2125. https://doi.org/10.1126/science.289.5487.2122
Caprio, M., Isidori, A. M., Carta, A. R., Moretti, C., Dufau, M. L., & Fabbri, A. (1999). Expression of functional leptin receptors in rodent Leydig cells. Endocrinology, 140(11), 4939–4947. https://doi.org/10.1210/endo.140.11.7088
Cavalli, A., Del Vecchio, L., & Locatelli, F. (2010). Geriatric nephrology. Journal of Nephrology, 23 Suppl 15, S11-15.
Dandona, P., & Dhindsa, S. (2011). Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. The Journal of Clinical Endocrinology and Metabolism, 96(9), 2643–2651. https://doi.org/10.1210/jc.2010-2724
Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006). Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA, 295(11), 1288–1299. https://doi.org/10.1001/jama.295.11.1288
Gaba, A., Mairhofer, M., Zhegu, Z., Leditznig, N., Szabo, L., Tschugguel, W., Schneeberger, C., & Yotova, I. (2018). Testosterone-induced downregulation of migration and proliferation in human Umbilical Vein Endothelial Cells by Androgen Receptor dependent and independent mechanisms. Molecular and Cellular Endocrinology, 476, 173–184. https://doi.org/10.1016/j.mce.2018.05.007
Handelsman, D. J. (1985). Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis, and renal transplantation. Endocrine Reviews, 6(2), 151–182. https://doi.org/10.1210/edrv-6-2-151
Handelsman, D. J., & Liu, P. Y. (1998). Androgen therapy in chronic renal failure. Bailliere’s Clinical Endocrinology and Metabolism, 12(3), 485–500. https://doi.org/10.1016/s0950-351x(98)80248-6
Hotta, Y., Kataoka, T., & Kimura, K. (2019). Testosterone Deficiency and Endothelial Dysfunction: Nitric Oxide, Asymmetric Dimethylarginine, and Endothelial Progenitor Cells. Sexual Medicine Reviews, 7(4), 661–668. https://doi.org/10.1016/j.sxmr.2019.02.005
Iglesias, P., Carrero, J. J., & Díez, J. J. (2012). Gonadal dysfunction in men with chronic kidney disease: Clinical features, prognostic implications, and therapeutic options. Journal of Nephrology, 25(1), 31–42. https://doi.org/10.5301/JN.2011.8481
Isidori, A. M., & Lenzi, A. (2005). Risk factors for androgen decline in older males: Lifestyle, chronic diseases, and drugs. Journal of Endocrinological Investigation, 28(3 Suppl), 14–22.
Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 116(23), 2694–2701. https://doi.org/10.1161/CIRCULATIONAHA.107.719005
Neuzillet, Y., Thuret, R., Kleinclauss, F., & Timsit, M.-O. (2016). [Andrologic consequences of chronic renal failure: State of the art for the yearly scientific report of the French National Association of Urology]. Progres En Urologie: Journal De l’Association Francaise D’urologie Et De La Societe Francaise D’urologie, 26(15), 1088–1093. https://doi.org/10.1016/j.purol.2016.08.013
Oueslati, I., Ounissi, M., Talbi, E., Azaiez, S., Bacha, M. M., & Ben Abdallah, T. (2020). Prevalence and risk factors of hypogonadism in men with chronic renal failure. La Tunisie Medicale, 98(2), 138–143.
Pitteloud, N., Hardin, M., Dwyer, A. A., Valassi, E., Yialamas, M., Elahi, D., & Hayes, F. J. (2005). Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. The Journal of Clinical Endocrinology and Metabolism, 90(5), 2636–2641. https://doi.org/10.1210/jc.2004-2190
van der Burgh AC, Khan SR, Neggers SJCMM, Hoorn EJ, Chaker L. (2022). The role of serum testosterone and dehydroepiandrosterone sulfate in kidney function and clinical outcomes in chronic kidney disease: a systematic review and meta-analysis. Endocr Connect, 11(6): e220061. Published 2022 Jun 23. doi:10.1530/EC-22-0061
Vaziri, N. D. (2004). Oxidative stress in uremia: Nature, mechanisms, and potential consequences. Seminars in Nephrology, 24(5), 469–473. https://doi.org/10.1016/j.semnephrol.2004.06.026
Vilar, L., Vilar, C. F., Lyra, R., & Freitas, M. da C. (2019). Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology, 109(1), 7–19. https://doi.org/10.1159/000499694
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Savas Karatas, Sennur Kose
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
